These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38665844)
1. Discovery of novel SOS1 inhibitors using machine learning. Duo L; Chen Y; Liu Q; Ma Z; Farjudian A; Ho WY; Low SS; Ren J; Hirst JD; Xie H; Tang B RSC Med Chem; 2024 Apr; 15(4):1392-1403. PubMed ID: 38665844 [TBL] [Abstract][Full Text] [Related]
2. Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature. Thompson SK; Buckl A; Dossetter AG; Griffen E; Gill A Expert Opin Ther Pat; 2021 Dec; 31(12):1189-1204. PubMed ID: 34253125 [No Abstract] [Full Text] [Related]
3. Targeting RAS oncogenesis with SOS1 inhibitors. Hillig RC; Bader B Adv Cancer Res; 2022; 153():169-203. PubMed ID: 35101230 [TBL] [Abstract][Full Text] [Related]
4. Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR. He H; Chen R; Wang Z; Qing L; Zhang Y; Liu Y; Pan W; Fang H; Zhang S Bioorg Chem; 2023 Jul; 136():106536. PubMed ID: 37054529 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers. Chen T; Tang X; Wang Z; Feng F; Xu C; Zhao Q; Wu Y; Sun H; Chen Y Eur J Med Chem; 2023 Dec; 261():115828. PubMed ID: 37778239 [TBL] [Abstract][Full Text] [Related]
6. Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth. Begovich K; Schoolmeesters A; Rajapakse N; Martinez-Terroba E; Kumar M; Shakya A; Lai C; Greene S; Whitefield B; Okano A; Mali V; Huang S; Chourasia AH; Fung L Mol Cancer Ther; 2024 Apr; 23(4):407-420. PubMed ID: 38224565 [TBL] [Abstract][Full Text] [Related]
7. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722 [TBL] [Abstract][Full Text] [Related]
8. Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRAS Luo L; Zheng T; Wang Q; Liao Y; Zheng X; Zhong A; Huang Z; Luo H Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631410 [TBL] [Abstract][Full Text] [Related]
9. Identifying Potential SOS1 Inhibitors via Virtual Screening of Multiple Small Molecule Libraries against KRAS-SOS1 Interaction. Ikram S; Sayyah E; Durdağı S Chembiochem; 2024 Jun; 25(12):e202400008. PubMed ID: 38622060 [TBL] [Abstract][Full Text] [Related]
10. Discovery of LHF418 as a new potent SOS1 PROTAC degrader. Li H; Chai M; Chen Y; Zhou F; Ren X; Xu J; Wang J; Wang Z; Huang W Bioorg Med Chem; 2024 Apr; 103():117661. PubMed ID: 38489998 [TBL] [Abstract][Full Text] [Related]
11. Targeting Son of Sevenless 1: The pacemaker of KRAS. Kessler D; Gerlach D; Kraut N; McConnell DB Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766 [TBL] [Abstract][Full Text] [Related]
13. Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery. Wu J; Li X; Wu C; Wang Y; Zhang J Eur J Med Chem; 2024 Mar; 268():116282. PubMed ID: 38430853 [TBL] [Abstract][Full Text] [Related]
14. Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma. He H; Zhang Y; Xu J; Li Y; Fang H; Liu Y; Zhang S J Med Chem; 2022 Oct; 65(19):13158-13171. PubMed ID: 36173339 [TBL] [Abstract][Full Text] [Related]
15. High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. Burns MC; Howes JE; Sun Q; Little AJ; Camper DV; Abbott JR; Phan J; Lee T; Waterson AG; Rossanese OW; Fesik SW Anal Biochem; 2018 May; 548():44-52. PubMed ID: 29444450 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of dual son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR) inhibitors for the treatment of cancers. Zeng Y; Huang C; Hou Q; Jiang W; Cheng J; Wu X Bioorg Chem; 2024 Dec; 153():107833. PubMed ID: 39357170 [TBL] [Abstract][Full Text] [Related]
17. From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Chen Y; Liu QP; Xie H; Ding J Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578 [TBL] [Abstract][Full Text] [Related]
18. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer. Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL Elife; 2020 Sep; 9():. PubMed ID: 32897190 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of quinazoline SOS1 inhibitors. Jiang H; Fan Y; Wang X; Wang J; Yang H; Fan W; Tang C Bioorg Med Chem Lett; 2023 May; 88():129265. PubMed ID: 37011767 [TBL] [Abstract][Full Text] [Related]
20. Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling. Luo G; Wang B; Hou Q; Wu X J Med Chem; 2023 Apr; 66(7):4324-4341. PubMed ID: 36987571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]